medigraphic.com
Centro Universitario de Ciencias de la Salud de la Universidad de Guadalajara y del OPD Hospitales Civiles de Guadalajara

2007, Number 2

<< Back Next >>

Inv Salud 2007; 9 (2)

CYP2D6 Genotype in Mennonites of Caucasian Origin of Durango State, Mexico

Alanis BRE, Lares AI, Sosa MM, Bradley ÁF, Lazalde RB

Language: Spanish
References: 27
Page: 100-103
PDF size: 185.55 Kb.


ABSTRACT

The isoenzima CYP2D6 metabolize different drugs and other xenobiotics compounds. The CYP2D6 gene locus is highly polymorphic, and results in variable enzymatic activity reflected in different phenotypes like ultrarapid metabolizer (UM) and poor metabolizer (PM). Far less, there is not information about CYP2D6 genotypification in the Menonitas population from the Durango State. The aim of the present work was to identify the allele frequencies of CYP2D6*4, *6 and *10 in 21 Mexican Menonitas by PCR and RFLP. The frequencies of the CYP2D6*4 and CYP2D6*10 alleles were 0.21 and 0.05 respectively. The *6 was not identified in any of the studied individual. The allelics frequencies of the variants *4 and *10 in Mexicam Menonitas were similar with the frequencies reported to Caucasians. The detection of this genotype allows predicting 4.7% of PM in this population, similar to the frequency of PM observed in Europe and North America Caucasians (5-10%).


REFERENCES

  1. Zanger UM, Raimundo S, Eichelbaum M. “Cytochrome P450 2D6: overview band update on pharmacology, genetics, biochemistry”. Arch Pharmacol, 2004, 369:23-37.

  2. Sams C, Mason HJ, Rawbone R. “Evidence for the activation of organophosphate pesticides by cytochrome P450 3A4 and 2D6 in human liver microsomes”. Toxic Lett, 2000, 116:217-221.

  3. Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ. “A tabacco smokederived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6”. Carcinogenesis, 1991, 12:(7) 1197-1201.

  4. Ingelman-Sundberg M, Daly AK, Nebert DW. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.imm.ki.se/cypalleles/.

  5. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics, 1999, 9:669-682.

  6. Masimirembwa CM, Hasler JA. “Genetic polymorphism of drug metabolizing enzymes in African populations: implications for the use of neuroleptics and antidepressants”. Brain Res Bull, 1997, 44:561-571.

  7. Sosa-Macias M, Elizondo G, Flores-Perez C, Flores-Perez J, Bradley-Alvarez F, Alanis-Bañuelos RE, Lares-Asseff I. “CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico”. J Clin Pharmacol, 2006, 46:527-36.

  8. López M, Guerrero J, Jung-Cook H, Alonso ME. “CYP2D6 genotype and phenotype determination in a Mexican Mestizo population”. Eur J Clin Pharmacol, 2005, 61:749-754.

  9. Arias TD, Jorge LF, Lee D, Barrantes R, Inaba T. “The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolizers”. Clin Pharmacol Ther, 1988, 43:456-465.

  10. Arias TD, Inaba T, Cooke RG, Jorge LF. “A preliminary note on the transient polymorphic oxidation of sparteine in the Ngawbe Guaymí Amerindians: a case of genetic divergence with tentative phylogenetic time frame for the pathway”. Clin Pharmacol Ther, 1988, 44:343-351.

  11. Jorge LF, Eichelbaum M, Griese EU, Inaba T, Arias TD. “Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations”. Pharmacogenetics, 1999, 9:217-228.

  12. Arredondo López Adelina. Pasado y presente de los menonitas mexicanos. México desconocido, 1995, noviembre 225, también disponible en: www.mexicodesconocido.com.mx/espanol/cultura_y_sociedad/fiestas_y_tradiciones/detalle.cfm?idpag=3720&idsec=15&idsub=68.

  13. Jaworski MA, Severini A, Mansour G, Konrad H.M, Slater J, Hennig K, Schlaut J, Yoon JW, Pak CY, Maclaren N, et al. “Genetic conditions among canadian mennonites: evidence for a founder effect among the old colony (chortitza) mennonites”. Clin Invest Med, 1989, 12: (2)127-41.

  14. Daly AK, Monkman SC, Smart J, Steward A, Cholerton S. “Analysis of Cytochrome P450 Polymorphisms”, en: “Philips IR y Shephard EA, compiladores”. Cytochrome P450 Protocols (Methods in Molecular Biology).Totowa NJ; 1998. 406-408.

  15. Sachse C, Brockmoller J, Bauer S, Roots I. “Cytochrome P450 2D6 variants in a caucasian population: Allele frequencies and Phenotypic consequences”. Am J Hum Genet, 1997, 60:284-295.

  16. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmoller J, Frotschl R, Kopke K, Gerloff T, Chernov JN, Roots I. “Polymorphisms of drugmetabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a russian population”. Eur J Clin Pharmacol, 2003, 59: (4) 303-312

  17. Niewinski P, Orzechowska-Juzwenko K, Hurkacz M, Rzemislawska Z, Jazwinska-Tarnawska E, Milejski P, Forkasiewicz Z. “CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a polish population”. Eur J Clin Pharmacol, 2002, 58: (8) 533-535.

  18. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. “Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequency of CYP2D6”. Clin Pharmacol Ther, 1993, 53: 410-418.

  19. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. “Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes in subjects with diminished capacity for debrisoquine hydroxylation”. Mol Pharmacol, 1994, 46: 452-459.

  20. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F, Bertilsson L. “Genetic analysis of CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects”. Pharmacogenetics, 1995, 5: 159-64.

  21. Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK. “CYP2D6 phenotype-genotype relationship in African-Americans and Caucasians in Los Angeles”. Pharmacogenetics, 1998, 8:529-541.

  22. Griese UE, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M. “Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population”. Pharmacogenetics, 1999, 9:715-723.

  23. Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, Stavljenic-Rukavina A. “Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19 and CYP2D6 in Croatian population”. Croat Med J, 2002, 44: (4) 425-4258.

  24. Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schroder T, Kayaalp SO, Roots I, Brockmoller J. “Low frequency of detective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population”. Clin Pharmacol Ther, 1999, 66: (2)185-192.

  25. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Morike K, Stuven T, Eichelbaum M. “Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population”. Pharmacogenetics, 1998, 8:15-26.

  26. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. “Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequency of CYP2D6”. Clin Pharmacol Ther, 1993, 53: 410-418.

  27. Armstrong M, Idle JR, Daly AK. “A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction”. Hum Genet, 1993, 91:616-617.




2020     |     www.medigraphic.com